Skip to Content

Laquinimod Approval Status

FDA Approved: No
Generic name: laquinimod
Company: Teva Pharmaceutical Industries Ltd. and Active Biotech
Treatment for: Multiple Sclerosis, Huntington's Disease

Laquinimod is an oral, CNS-active immunomodulator in development for the treatment of relapsing-remitting multiple sclerosis (RRMS), primary-progressive multiple sclerosis (PPMS) and Huntington disease.

Development Status and FDA Approval Process for laquinimod

DateArticle
May  5, 2017Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint
Jan  4, 2016Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials
Jun 25, 2015Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide